Related Experiment Video
Updated: Aug 9, 2025
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
6.9K
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases
1Department of Dermatology IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08041 Barcelona, Spain.
International Journal of Molecular Sciences
|February 25, 2023
Summary
Tyrosine kinase 2 (Tyk2) inhibitors offer a novel therapeutic approach for immune-mediated inflammatory diseases. Deucravacitinib, a selective Tyk2 inhibitor, is approved for psoriasis, showing promise for future treatments.
Area of Science:
- Immunology
- Pharmacology
- Dermatology
Background:
- Janus kinase (Jak)/signal transducer and activating protein (STAT) pathways are crucial for cytokine signaling in cellular processes.
- These pathways are implicated in physiological and inflammatory cascades, driving research into novel therapies for immune-mediated inflammatory diseases (IMID).
- Tyrosine kinase 2 (Tyk2) dysfunction is linked to protection from psoriasis and IMID prevention without increasing infection risk.
Purpose of the Study:
- To highlight Tyrosine kinase 2 (Tyk2) inhibition as a promising therapeutic target for immune-mediated inflammatory diseases.
- To differentiate deucravacitinib's allosteric inhibition mechanism from traditional orthosteric inhibitors.
- To discuss the potential of Tyk2 inhibitors in treating various conditions.
Main Methods:
- Review of existing literature on Jak/STAT pathways and Tyk2 inhibitors.
- Comparison of orthosteric and allosteric inhibition mechanisms.
- Analysis of deucravacitinib's unique binding to the Tyk2 JH2 domain.
Main Results:
- Tyk2 dysfunction confers protection against psoriasis and IMID.
- Orthosteric Tyk2 inhibitors targeting the JH1 domain lack selectivity.
- Deucravacitinib, an allosteric inhibitor targeting the JH2 domain, offers greater selectivity and a reduced adverse event profile.
- Deucravacitinib received FDA approval in September 2022 for moderate-to-severe psoriasis.
Conclusions:
- Tyk2 inhibition represents a significant therapeutic advancement for IMID.
- Deucravacitinib's allosteric mechanism provides a more selective and safer approach.
- The development of Tyk2 inhibitors is expected to expand to new indications and drug candidates.
More Related Videos
Related Concept Videos
01:24T Cell Types and Functions
1.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
01:27Cytotoxic T Cells-mediated Immune Response
1.1K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K
01:27Tumor Immunotherapy
611
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
611
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.6K
01:20The JAK-STAT Signaling Pathway
9.1K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.1K